Company
Every investor coverage indicates participated in a round Booster Financial Services raised.
Companies Booster Financial Services acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Booster Financial Services. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Brandon Capital's site announces it led $14m for Amaroq Therapeutics, an Otago spinout developing RNA-based cancer treatments — the firm's first deal as a government-backed incubator. The piece also recalls Kea Therapeutics' shutdown.
Brandon Capital led a NZ$14 million investment in Amaroq Therapeutics, a University of Otago spinout developing RNA cancer therapies, with three co-investors and a Callaghan Innovation repayable grant supporting the deal.